| Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s proprietary drugs and drug candidates that have either received regulatory approval or are being developed by Co. or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology. We show 39 historical shares outstanding datapoints in our NKTR shares outstanding history coverage, used to compute NKTR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NKTR market cap history over the course of time is important for investors
interested in comparing NKTR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NKTR versus a peer is one thing; comparing
NKTR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NKTR can fluctuate over the course of history.
With this page we aim to empower investors researching NKTR by allowing them to research the NKTR market cap history.